Skip Navigation

Jeffrey A. Meyerhardt, MD, MPH


Medical Oncology

Make an Appointment

Physician

  • Clinical Director, Gastrointestinal Cancer Center
  • Deputy Clinical Research Officer
  • Douglas Gray Woodruff Chair in Colorectal Cancer Research
  • Senior Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gastrointestinal cancers

Contact Information

  • Appointments(877) 332-4294 (new)
    (617) 632-5929 (current)
  • Office Phone Number617-632-6855
  • Fax617-632-5370

Bio

Dr. Meyerhardt received his MD from Yale School of Medicine in 1997. He completed a residency in internal medicine at Beth Israel Deaconness Medical Center, in Boston, followed by a medical oncology fellowship at DFCI. He joined the Gastrointestinal Cancer Center at DFCI in 2002..

Board Certification:

  • Medical Oncology, 2003

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology

Residency:

  • Beth Israel Deaconess Medical Center, Internal Medicine

Medical School:

  • Yale University School of Medicine

Recent Awards:

  • Irving Jancock Fellow, Dana-Farber Cancer Institute 2002
  • Tisch Outstanding Achievement Award 2004
  • The George P. Canellos Award for Excellence In Clinical Investigation and Patient Care (2006)

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Diet and Lifestyle Studies in Patients with Colorectal Cancer

We have a strong interest in the influence of diet and lifestyle on outcomes among patients with colorectal cancer. While much research has focused on the impact of host factors on the risk of developing colorectal cancer, little data are available to suggest how these factors impact on treatment-related toxicities or long-term outcomes among patients already diagnosed with the disease. Using databases from large oncology cooperative group trials, the Nurses Health Study, and Health Professionals Follow-up Study, we have analyzed the influence of diet and lifestyle on outcomes in early-stage colorectal cancer patients. We have been involved in studies of physical activity, diet, smoking, obesity, weight change, COX inhibitors and vitamin D in colorectal cancer survivors. Based on these studies, I am the principal investigator of a national randomized trial (CALGB 80702) that will test celecoxib as adjunctive therapy to standard treatment for stage III colon cancer. The trial is under development with the National Cancer Institute.

I serve as a Project co-Leader for the Gastrointestinal Cancer SPORE of Dana-Farber / Harvard Cancer Center. We are studying molecular pathways associated with sensitivity and resistance to monoclonal antibodies against the epidermal growth factor receptor for colorectal cancer.

Finally, I am involved in mid-stage testing of novel agents for colorectal cancer. I have served as the principal investigator and co-investigator on multiple phase I / II trials

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz L, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA. Marine ?-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 Jan 22.
View in: PubMed

Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, Giovannucci EL, Chan AT. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. 2018 Jan 01; 4(1):71-79.
View in: PubMed

Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeeff S, Corley D, Weltzien E, Castillo AL, Caan BJ. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017 12 01; 3(12):e172319.
View in: PubMed

Trudel-Fitzgerald C, Tworoger SS, Poole EM, Zhang X, Giovannucci EL, Meyerhardt JA, Kubzansky LD. Psychological Symptoms and Subsequent Healthy Lifestyle After a Colorectal Cancer Diagnosis. Health Psychol. 2017 Nov 20.
View in: PubMed

Simon TG, King LY, Chong DQ, Nguyen L, Ma Y, VoPham T, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Khalili H, Chung RT, Zhang X, Chan AT. Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies. Hepatology. 2017 Nov 20.
View in: PubMed

Hu Y, Ding M, Yuan C, Wu K, Smith-Warner SA, Hu FB, Chan AT, Meyerhardt JA, Ogino S, Fuchs CS, Giovannucci EL, Song M. Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. Gastroenterology. 2017 Nov 20.
View in: PubMed

Rosenberg SM, Ligibel JA, Meyerhardt JA, Jacobsen ED, Garber JE, Nekhlyudov L, Bunnell CA, Nutting P, Sprunck-Harrild K, Walsh SK, Partridge AH. Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study. J Cancer Educ. 2017 Oct 20.
View in: PubMed

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
View in: PubMed

Caan BJ, Meyerhardt JA, Prado CM. Explaining the Obesity Paradox-Response. Cancer Epidemiol Biomarkers Prev. 2017 10; 26(10):1576.
View in: PubMed

Momen-Heravi F, Masugi Y, Qian ZR, Nishihara R, Liu L, Smith-Warner SA, Keum N, Zhang L, Tchrakian N, Nowak JA, Yang W, Ma Y, Bowden M, da Silva A, Wang M, Fuchs CS, Meyerhardt JA, Ng K, Wu K, Giovannucci E, Ogino S, Zhang X. Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. Int J Cancer. 2017 Dec 15; 141(12):2471-2479.
View in: PubMed

Gu M, Nishihara R, Chen Y, Li W, Shi Y, Masugi Y, Hamada T, Kosumi K, Liu L, da Silva A, Nowak JA, Twombly T, Du C, Koh H, Li W, Meyerhardt JA, Wolpin BM, Giannakis M, Aguirre AJ, Bass AJ, Drew DA, Chan AT, Fuchs CS, Qian ZR, Ogino S. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Oct 20; 8(50):87379-87389.
View in: PubMed

McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2018 Jan; 9(1):24-31.
View in: PubMed

Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, Xiao J, Castillo AL, Caan BJ. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer. 2017 Dec 15; 123(24):4868-4877.
View in: PubMed

Yuan C, Bao Y, Sato K, Nimptsch K, Song M, Brand-Miller JC, Morales-Oyarvide V, Zoltick ES, Keum N, Wolpin BM, Meyerhardt JA, Chan AT, Willett WC, Stampfer MJ, Wu K, Giovannucci EL, Fuchs CS, Ng K. Influence of dietary insulin scores on survival in colorectal cancer patients. Br J Cancer. 2017 Sep 26; 117(7):1079-1087.
View in: PubMed

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
View in: PubMed

Lee MK, Kim JY, Kim DI, Kang DW, Park JH, Ahn KY, In Yang H, Lee DH, Roh YH, Lee JW, Chu SH, Meyerhardt JA, Jones LW, Kim NK, Jeon JY. Effect of home-based exercise intervention on fasting insulin and Adipocytokines in colorectal cancer survivors: a randomized controlled trial. Metabolism. 2017 Nov; 76:23-31.
View in: PubMed

Yang W, Liu L, Masugi Y, Qian ZR, Nishihara R, Keum N, Wu K, Smith-Warner S, Ma Y, Nowak JA, Momen-Heravi F, Zhang L, Bowden M, Morikawa T, Silva AD, Wang M, Chan AT, Fuchs CS, Meyerhardt JA, Ng K, Giovannucci E, Ogino S, Zhang X. Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut. 2017 Jul 04.
View in: PubMed

Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, Nowak JA, Kosumi K, Hamada T, Masugi Y, Bullman S, Drew DA, Kostic AD, Fung TT, Garrett WS, Huttenhower C, Wu K, Meyerhardt JA, Zhang X, Willett WC, Giovannucci EL, Fuchs CS, Chan AT, Ogino S. Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. JAMA Oncol. 2017 Jul 01; 3(7):921-927.
View in: PubMed

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
View in: PubMed

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
View in: PubMed

Hanyuda A, Cao Y, Hamada T, Nowak JA, Qian ZR, Masugi Y, da Silva A, Liu L, Kosumi K, Soong TR, Jhun I, Wu K, Zhang X, Song M, Meyerhardt JA, Chan AT, Fuchs CS, Giovannucci EL, Ogino S, Nishihara R. Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status. Eur J Epidemiol. 2017 May; 32(5):393-407.
View in: PubMed

Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, Feliciano EC, Castillo AL, Quesenberry CP, Kwan ML, Prado CM. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017 Jul; 26(7):1008-1015.
View in: PubMed

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
View in: PubMed

Abrams TA, Meyer G, Meyerhardt JA, Wolpin BM, Schrag D, Fuchs CS. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Oncologist. 2017 Aug; 22(8):925-933.
View in: PubMed

Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol. 2017 Jun 01; 35(16):1836-1844.
View in: PubMed

Keum N, Yuan C, Nishihara R, Zoltick E, Hamada T, Martinez Fernandez A, Zhang X, Hanyuda A, Liu L, Kosumi K, Nowak JA, Jhun I, Soong TR, Morikawa T, Tabung FK, Qian ZR, Fuchs CS, Meyerhardt JA, Chan AT, Ng K, Ogino S, Giovannucci EL, Wu K. Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. Int J Cancer. 2017 06 15; 140(12):2648-2656.
View in: PubMed

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
View in: PubMed

Meyerhardt JA, Kroenke CH, Prado CM, Kwan ML, Castillo A, Weltzien E, Cespedes Feliciano EM, Xiao J, Caan BJ. Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiol Biomarkers Prev. 2017 Jan; 26(1):30-37.
View in: PubMed

Momen-Heravi F, Babic A, Tworoger SS, Zhang L, Wu K, Smith-Warner SA, Ogino S, Chan AT, Meyerhardt J, Giovannucci E, Fuchs C, Cho E, Michaud DS, Stampfer MJ, Yu YH, Kim D, Zhang X. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses' Health Study. Int J Cancer. 2017 Feb 01; 140(3):646-652.
View in: PubMed

Brown JC, Meyerhardt JA. Obesity and Energy Balance in GI Cancer. J Clin Oncol. 2016 Dec 10; 34(35):4217-4224.
View in: PubMed

Mima K, Cao Y, Chan AT, Qian ZR, Nowak JA, Masugi Y, Shi Y, Song M, da Silva A, Gu M, Li W, Hamada T, Kosumi K, Hanyuda A, Liu L, Kostic AD, Giannakis M, Bullman S, Brennan CA, Milner DA, Baba H, Garraway LA, Meyerhardt JA, Garrett WS, Huttenhower C, Meyerson M, Giovannucci EL, Fuchs CS, Nishihara R, Ogino S. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016 Nov 03; 7(11):e200.
View in: PubMed

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206.
View in: PubMed

Dou R, Nishihara R, Cao Y, Hamada T, Mima K, Masuda A, Masugi Y, Shi Y, Gu M, Li W, da Silva A, Nosho K, Zhang X, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Qian ZR, Ogino S. MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res. 2016 Nov; 4(11):927-935.
View in: PubMed

Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, Kwan ML, Xiao J, Quesenberry C, Weltzien EK, Castillo AL, Caan BJ. Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer. J Clin Oncol. 2016 Sep 06.
View in: PubMed

Kroenke CH, Neugebauer R, Meyerhardt J, Prado CM, Weltzien E, Kwan ML, Xiao J, Caan BJ. Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams. JAMA Oncol. 2016 Sep 01; 2(9):1137-45.
View in: PubMed

Mima K, Nowak JA, Qian ZR, Cao Y, Song M, Masugi Y, Shi Y, da Silva A, Gu M, Li W, Hamada T, Zhang X, Wu K, Meyerhardt JA, Baba H, Giovannucci EL, Chan AT, Fuchs CS, Ogino S, Nishihara R. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016 Aug 23; 7(34):55098-55109.
View in: PubMed

Song M, Zhang X, Meyerhardt JA, Giovannucci EL, Ogino S, Fuchs CS, Chan AT. Marine ?-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut. 2017 Oct; 66(10):1790-1796.
View in: PubMed

Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468.
View in: PubMed

Kocarnik JM, Chan AT, Slattery ML, Potter JD, Meyerhardt J, Phipps A, Nan H, Harrison T, Rohan TE, Qi L, Hou L, Caan B, Kroenke CH, Strickler H, Hayes RB, Schoen RE, Chong DQ, White E, Berndt SI, Peters U, Newcomb PA. Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage-specific associations. Int J Cancer. 2016 09 01; 139(5):1065-72.
View in: PubMed

Hanyuda A, Ogino S, Qian ZR, Nishihara R, Song M, Mima K, Inamura K, Masugi Y, Wu K, Meyerhardt JA, Chan AT, Fuchs CS, Giovannucci EL, Cao Y. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer. 2016 08 15; 139(4):854-68.
View in: PubMed

Morales-Oyarvide V, Meyerhardt JA, Ng K. Vitamin D and Physical Activity in Patients With Colorectal Cancer: Epidemiological Evidence and Therapeutic Implications. Cancer J. 2016 May-Jun; 22(3):223-31.
View in: PubMed

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 Apr 14.
View in: PubMed

Babic A, Shah SM, Song M, Wu K, Meyerhardt JA, Ogino S, Yuan C, Giovannucci EL, Chan AT, Stampfer MJ, Fuchs CS, Ng K. Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer. 2016 Apr 26; 114(9):995-1002.
View in: PubMed

Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, da Silva A, Cao Y, Song M, Nowak J, Gu M, Li W, Morikawa T, Zhang X, Wu K, Baba H, Giovannucci EL, Meyerhardt JA, Chan AT, Fuchs CS, Qian ZR, Ogino S. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res. 2016 Aug 01; 22(15):3841-8.
View in: PubMed

Ahn KY, Lee MK, Kim DI, Park J, Min J, In Yang H, Lee J, Oh M, An J, Lee JW, Chu SH, Meyerhardt JA, Kim NK, Jeon JY. Cardiopulmonary fitness, adiponectin, chemerin associated fasting insulin level in colorectal cancer patients. Support Care Cancer. 2016 07; 24(7):2927-35.
View in: PubMed

Hanyuda A, Kim SA, Martinez-Fernandez A, Qian ZR, Yamauchi M, Nishihara R, Morikawa T, Liao X, Inamura K, Mima K, Cao Y, Zhang X, Wu K, Chan AT, Giovannucci EL, Meyerhardt JA, Fuchs CS, Shivdasani RA, Ogino S. Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol. 2016 Mar; 23(3):908-17.
View in: PubMed

McCleary NJ, Sato K, Nishihara R, Inamura K, Morikawa T, Zhang X, Wu K, Yamauchi M, Kim SA, Sukawa Y, Mima K, Qian ZR, Fuchs CS, Ogino S, Meyerhardt JA. Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1489-98.
View in: PubMed

Meyerhardt JA. What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle? Clin Adv Hematol Oncol. 2015 Oct; 13(10):636-8.
View in: PubMed

Lochhead P, Nishihara R, Qian ZR, Mima K, Cao Y, Sukawa Y, Kim SA, Inamura K, Zhang X, Wu K, Giovannucci E, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. Am J Clin Nutr. 2015 Nov; 102(5):1134-41.
View in: PubMed

Chong DQ, Mehta RS, Song M, Kedrin D, Meyerhardt JA, Ng K, Wu K, Fuchs CS, Giovannucci EL, Ogino S, Chan AT. Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prev Res (Phila). 2015 Dec; 8(12):1138-45.
View in: PubMed

Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 Dec; 65(12):1973-1980.
View in: PubMed

Cao Y, Meyerhardt JA, Chan AT, Wu K, Fuchs CS, Giovannucci EL. Television watching and colorectal cancer survival in men. Cancer Causes Control. 2015 Oct; 26(10):1467-76.
View in: PubMed

Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
View in: PubMed

Rosenthal MH, Kim KW, Fuchs CS, Meyerhardt JA, Ramaiya NH. CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer. Abdom Imaging. 2015 Jun; 40(5):1170-6.
View in: PubMed

Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, Qian Z, Morikawa T, Wu K, Giovannucci EL, Fuchs CS, Ogino S, Chan AT. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. Gastroenterology. 2015 Sep; 149(3):614-22.
View in: PubMed

Meyerhardt JA, Tepper JE, Venook AP. Special Series: Advances in GI Cancer. J Clin Oncol. 2015 Jun 01; 33(16):1717-20.
View in: PubMed

Van Blarigan EL, Meyerhardt JA. Role of physical activity and diet after colorectal cancer diagnosis. J Clin Oncol. 2015 Jun 01; 33(16):1825-34.
View in: PubMed

McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med. 2015 Jul; 29(6):535-42.
View in: PubMed

Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One. 2015; 10(3):e0120706.
View in: PubMed

Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, Stout NL, Kvale E, Ganzer H, Ligibel JA. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015 May-Jun; 65(3):167-89.
View in: PubMed

Lee J, Jeon JY, Meyerhardt JA. Diet and lifestyle in survivors of colorectal cancer. Hematol Oncol Clin North Am. 2015 Feb; 29(1):1-27.
View in: PubMed

Fung TT, Kashambwa R, Sato K, Chiuve SE, Fuchs CS, Wu K, Giovannucci E, Ogino S, Hu FB, Meyerhardt JA. Post diagnosis diet quality and colorectal cancer survival in women. PLoS One. 2014; 9(12):e115377.
View in: PubMed

Rosenthal MH, Kim KW, Fuchs CS, Meyerhardt JA, Ramaiya NH. Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer. Abdom Imaging. 2014 Dec; 39(6):1261-6.
View in: PubMed

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
View in: PubMed

Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol. 2015 Apr; 22(4):1226-1235.
View in: PubMed

Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian ZR, Kuchiba A, Kim SA, Mima K, Sukawa Y, Jung S, Zhang X, Wu K, Cho E, Chan AT, Meyerhardt JA, Harris CC, Fuchs CS, Ogino S. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014 Sep; 106(9).
View in: PubMed

Lochhead P, Meyerhardt JA, Fuchs CS, Ogino S. Response. J Natl Cancer Inst. 2014 Aug; 106(8).
View in: PubMed

Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S, Qian ZR. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol. 2014 Dec; 21(13):4164-73.
View in: PubMed

Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
View in: PubMed

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014 May 31; 13:135.
View in: PubMed

Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
View in: PubMed

Meyerhardt JA, Benson AB, Mangu PB. Reply to C.C. Earle. J Clin Oncol. 2014 May 10; 32(14):1518-9.
View in: PubMed

Jeon JY, Meyerhardt JA. Can we change the past for colorectal cancer patients and how do we move forward? Cancer. 2014 May 15; 120(10):1450-2.
View in: PubMed

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014 Feb; 106(2):djt371.
View in: PubMed

Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, Schrag D. Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol. 2014 Feb 20; 32(6):496-503.
View in: PubMed

Ng K, Scott JB, Drake BF, Chan AT, Hollis BW, Chandler PD, Bennett GG, Giovannucci EL, Gonzalez-Suarez E, Meyerhardt JA, Emmons KM, Fuchs CS. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr. 2014 Mar; 99(3):587-98.
View in: PubMed

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
View in: PubMed

Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10; 31(35):4465-70.
View in: PubMed

Clancy TE, Meyerhardt JA. Perioperative chemotherapy for colorectal cancer liver metastases. Oncology (Williston Park). 2013 Nov; 27(11):1088-90.
View in: PubMed

Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
View in: PubMed

Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013 Aug 07; 105(15):1151-6.
View in: PubMed

Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer. 2013 Oct 15; 133(8):1905-13.
View in: PubMed

Meyerhardt JA. We are what we eat, or are we? J Clin Oncol. 2013 Aug 01; 31(22):2763-4.
View in: PubMed

Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014 Jun 05; 33(23):2949-55.
View in: PubMed

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013 Sep 01; 119(17):3212-8.
View in: PubMed

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013 Jul 10; 31(20):2600-6.
View in: PubMed

Jeon JY, Meyerhardt JA. Exercise after cancer diagnosis: time to get moving. Oncology (Williston Park). 2013 Jun; 27(6):585-6, 588.
View in: PubMed

Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013 Jun; 20(3):383-90.
View in: PubMed

Lee DH, Kim JY, Lee MK, Lee C, Min JH, Jeong DH, Lee JW, Chu SH, Meyerhardt JA, Ligibel J, Jones LW, Kim NK, Jeon JY. Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. Support Care Cancer. 2013 Sep; 21(9):2537-45.
View in: PubMed

Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1142-52.
View in: PubMed

Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
View in: PubMed

Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):508-16.
View in: PubMed

Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with ß-catenin (CTNNB1) status. Cancer Res. 2013 Mar 01; 73(5):1600-10.
View in: PubMed

Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7.
View in: PubMed

Ahn KY, Hur H, Kim DH, Min J, Jeong DH, Chu SH, Lee JW, Ligibel JA, Meyerhardt JA, Jones LW, Jeon JY, Kim NK. The effects of inpatient exercise therapy on the length of hospital stay in stages I-III colon cancer patients: randomized controlled trial. Int J Colorectal Dis. 2013 May; 28(5):643-51.
View in: PubMed

Jeon JY, Jeong DH, Park MG, Lee JW, Chu SH, Park JH, Lee MK, Sato K, Ligibel JA, Meyerhardt JA, Kim NK. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PLoS One. 2013; 8(2):e55196.
View in: PubMed

Patterson RE, Colditz GA, Hu FB, Schmitz KH, Ahima RS, Brownson RC, Carson KR, Chavarro JE, Chodosh LA, Gehlert S, Gill J, Glanz K, Haire-Joshu D, Herbst KL, Hoehner CM, Hovmand PS, Irwin ML, Jacobs LA, James AS, Jones LW, Kerr J, Kibel AS, King IB, Ligibel JA, Meyerhardt JA, Natarajan L, Neuhouser ML, Olefsky JM, Proctor EK, Redline S, Rock CL, Rosner B, Sarwer DB, Schwartz JS, Sears DD, Sesso HD, Stampfer MJ, Subramanian SV, Taveras EM, Tchou J, Thompson B, Troxel AB, Wessling-Resnick M, Wolin KY, Thornquist MD. The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design. Cancer Causes Control. 2013 Apr; 24(4):695-704.
View in: PubMed

Meyerhardt JA. The impact of glycemic levels in patients with colon cancer. Clin Adv Hematol Oncol. 2013 Feb; 11(2):93-4.
View in: PubMed

Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
View in: PubMed

Je Y, Lee JE, Ma J, Zhang X, Cho E, Rosner B, Selhub J, Fuchs CS, Meyerhardt J, Giovannucci E. Prediagnostic plasma vitamin B6 (pyridoxal 5'-phosphate) and survival in patients with colorectal cancer. Cancer Causes Control. 2013 Apr; 24(4):719-29.
View in: PubMed

Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013 Jun; 12(2):95-102.
View in: PubMed

Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013 Apr; 26(4):465-84.
View in: PubMed

Chung JY, Lee DH, Park JH, Lee MK, Kang DW, Min J, Kim DI, Jeong DH, Kim NK, Meyerhardt JA, Jones LW, Jeon JY. Patterns of physical activity participation across the cancer trajectory in colorectal cancer survivors. Support Care Cancer. 2013 Jun; 21(6):1605-12.
View in: PubMed

McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
View in: PubMed

McCleary NJ, Hurria A, Meyerhardt J. In reply. Oncologist. 2013; 18(12):1331.
View in: PubMed

André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9:261-269.
View in: PubMed

Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T, Yamauchi M, Liao X, Qian ZR, Sun R, Sato K, Kirkner GJ, Wang M, Spiegelman D, Meyerhardt JA, Schernhammer ES, Chan AT, Giovannucci E, Fuchs CS. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst. 2013 Jan 16; 105(2):130-40.
View in: PubMed

Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012 Nov 21; 104(22):1702-11.
View in: PubMed

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012 Oct 25; 367(17):1596-606.
View in: PubMed

McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013 Mar; 12(1):62-9.
View in: PubMed

Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg. 2012 Aug; 147(8):715-23.
View in: PubMed

Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012 Dec; 48(18):3405-13.
View in: PubMed

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8.
View in: PubMed

Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012 Sep 01; 18(17):4753-63.
View in: PubMed

Demark-Wahnefried W, Platz EA, Ligibel JA, Blair CK, Courneya KS, Meyerhardt JA, Ganz PA, Rock CL, Schmitz KH, Wadden T, Philip EJ, Wolfe B, Gapstur SM, Ballard-Barbash R, McTiernan A, Minasian L, Nebeling L, Goodwin PJ. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1244-59.
View in: PubMed

Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
View in: PubMed

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012 Jul 20; 30(21):2624-34.
View in: PubMed

Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul-Aug; 62(4):243-74.
View in: PubMed

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012 Apr 15; 18(8):2257-68.
View in: PubMed

Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst. 2012 Mar 07; 104(5):415-20.
View in: PubMed

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012 Feb 08; 104(3):211-27.
View in: PubMed

Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012 Feb 20; 30(6):608-15.
View in: PubMed

André T, O'Neil BH, Meyerhardt JA. Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next. Am Soc Clin Oncol Educ Book. 2012; 223-30.
View in: PubMed

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
View in: PubMed

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist. 2012; 17(1):14-e35.
View in: PubMed

Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012 Jun; 19(6):1944-53.
View in: PubMed

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
View in: PubMed

Jeon JY, Meyerhardt JA. Energy in and energy out: what matters for survivors of colorectal cancer? J Clin Oncol. 2012 Jan 01; 30(1):7-10.
View in: PubMed

Ligibel JA, Meyerhardt J, Pierce JP, Najita J, Shockro L, Campbell N, Newman VA, Barbier L, Hacker E, Wood M, Marshall J, Paskett E, Shapiro C. Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. Breast Cancer Res Treat. 2012 Feb; 132(1):205-13.
View in: PubMed

Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012 Sep 01; 131(5):1169-78.
View in: PubMed

Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011 Nov; 121(11):4311-21.
View in: PubMed

Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One. 2011; 6(9):e25062.
View in: PubMed

Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
View in: PubMed

Meyerhardt JA. Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol. 2011 Aug; 38(4):533-41.
View in: PubMed

Bao Y, Nimptsch K, Chan AT, Ng K, Meyerhardt JA, Willett WC, Giovannucci E, Fuchs CS. Reported behavior of eating anything at anytime and risk of colorectal cancer in women. Int J Cancer. 2012 Mar 15; 130(6):1395-400.
View in: PubMed

Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011 Aug 20; 29(24):3255-62.
View in: PubMed

Van Loon K, Wigler D, Niedzwiecki D, Hollis D, Venook AP, Blanke CD, Saltz L, Goldberg RM, Fuchs CS, Meyerhardt JA. A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. J Clin Oncol. 2011 May 20; 29(15_suppl):e14026.
View in: PubMed

Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102.
View in: PubMed

Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011 Apr 27; 305(16):1685-94.
View in: PubMed

Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20; 29(12):1599-606.
View in: PubMed

Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer. 2011 Mar 01; 128(5):1080-94.
View in: PubMed

Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun; 22(6):1367-73.
View in: PubMed

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010 Dec; 222(4):350-66.
View in: PubMed

Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011 Apr 01; 117(7):1399-408.
View in: PubMed

Meyerhardt JA. Adjuvant therapy for stage II and III colon cancer. Clin Adv Hematol Oncol. 2010 Nov; 8(11):772-4.
View in: PubMed

Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol. 2011 Aug; 68(2):293-300.
View in: PubMed

Bao Y, Nimptsch K, Meyerhardt JA, Chan AT, Ng K, Michaud DS, Brand-Miller JC, Willett WC, Giovannucci E, Fuchs CS. Dietary insulin load, dietary insulin index, and colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010 Dec; 19(12):3020-6.
View in: PubMed

Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103(7):1025-33.
View in: PubMed

Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010 Oct 01; 28(28):4354-63.
View in: PubMed

Goodwin PJ, Meyerhardt JA, Hursting SD. Host factors and cancer outcome. J Clin Oncol. 2010 Sep 10; 28(26):4019-21.
View in: PubMed

Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J Clin Oncol. 2010 Sep 10; 28(26):4066-73.
View in: PubMed

Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010 May; 176(5):2292-301.
View in: PubMed

McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, Hantel A, Benson A, Goldberg R, Meyerhardt JA. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 2010 Feb 15; 116(4):957-66.
View in: PubMed

McCleary NJ, Meyerhardt JA. New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient. Oncology (Williston Park). 2010 Jan; 24(1 Suppl 1):3-8.
View in: PubMed

Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009 Dec 14; 169(22):2102-8.
View in: PubMed

Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
View in: PubMed

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54.
View in: PubMed

Myers AP, Meyerhardt JA, Cantley LC. Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? Clin Cancer Res. 2009 Nov 15; 15(22):6748-50.
View in: PubMed

Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009 Oct 15; 15(20):6412-20.
View in: PubMed

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010 Feb; 105(2):420-33.
View in: PubMed

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2765-72.
View in: PubMed

Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL, Meyerhardt JA, Fuchs CS. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2513-21.
View in: PubMed

Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
View in: PubMed

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009 Sep 20; 27(27):4591-8.
View in: PubMed

Ng K, Wolpin BM, Meyerhardt JA, Wu K, Chan AT, Hollis BW, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009 Sep 15; 101(6):916-23.
View in: PubMed

Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009 Nov; 137(5):1609-20.e1-3.
View in: PubMed

Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 04; 101(3):465-72.
View in: PubMed

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009 Jul 15; 15(14):4665-73.
View in: PubMed

Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009 Jul 01; 15(13):4431-8.
View in: PubMed

Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009 Jun 15; 115(12):2617-29.
View in: PubMed

Ogino S, Shima K, Nosho K, Irahara N, Baba Y, Wolpin BM, Giovannucci EL, Meyerhardt JA, Fuchs CS. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1849-58.
View in: PubMed

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
View in: PubMed

Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
View in: PubMed

Jackson McCleary NA, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves C, Saltz L, Sargent D. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol. 2009 May 20; 27(15_suppl):4010.
View in: PubMed

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol. 2009 May 20; 27(15_suppl):4578.
View in: PubMed

Meyerhardt JA, Jackson McCleary N, Niedzwiecki D, Hollis D, Venook A, Mayer R, Goldberg R. Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. J Clin Oncol. 2009 May 20; 27(15_suppl):4038.
View in: PubMed

Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
View in: PubMed

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45.
View in: PubMed

Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008 Dec 15; 14(24):8263-9.
View in: PubMed

Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009 Jan 10; 27(2):176-85.
View in: PubMed

Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8.
View in: PubMed

Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26(35):5713-20.
View in: PubMed

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58(1):90-6.
View in: PubMed

Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
View in: PubMed

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008 Sep 01; 26(25):4109-15.
View in: PubMed

Wolpin BM, Wei EK, Ng K, Meyerhardt JA, Chan JA, Selhub J, Giovannucci EL, Fuchs CS. Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol. 2008 Jul 01; 26(19):3222-8.
View in: PubMed

Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008 Jun 20; 26(18):2984-91.
View in: PubMed

Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt JA. Comparing Safety and Efficacy of First-Line Irinotecan/Fluoropyrimidine Combinations in Elderly versus Nonelderly Patients with Metastatic Colorectal Cancer: Findings from the BICC-C Study. submitted. 2008.
View in: PubMed

Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23.
View in: PubMed

Wolpin BM, Hezel AF, Ryan DP, Abrams TA, Meyerhardt JA, Blaszkowsky LS, Clark JW, Allen B, Regan EM, Fuchs CS. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4614.
View in: PubMed

Jackson NA, Fuchs CS, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Meyerhardt JA. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. J Clin Oncol. 2008 May 20; 26(15_suppl):4039.
View in: PubMed

Bass AJ, Meyerhardt JA, Chan JA, Giovannucci EL, Fuchs CS. Family history and survival after colorectal cancer diagnosis. Cancer. 2008 Mar 15; 112(6):1222-9.
View in: PubMed

Meyerhardt JA. Trends in Colorectal Cancer. Am J of Hematology / Oncology. 2008; 7(3):82-83..
View in: PubMed

Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol. 2008 Mar; 21(3):245-55.
View in: PubMed

Kulke M, Chan JA, Meyerhardt JA, Zhu AX, Abrams T, Earle CC, Casey CM, Regan E, Sidor CF, Fuchs CS. Phase II study of 2-methoxyestradiol (2ME2), administered in combination with bevacizumab, in patients (Pts) with advanced carcinoid tumors. Gastrointestinal Cancer Sympsosium. 2008.
View in: PubMed

Wolpin B, Hezel AF, Ryan DP, Abrams TA, Meyerhardt JA, Blaszkowsky LS, Clark JW, Allen B, Regan EM, Fuchs CS. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 2008.
View in: PubMed

Meyerhardt JA. GI Cancers for the Boards. The Harvard Intensive Review of Internal Medicine (Ed: Singh A, Loscalzo J). 2008; In editorial stage..
View in: PubMed

Blaszkowsky LS, Zhu AX, Abrams TA, Earle CC, Kwak E, Hezel AF, Meyerhardt JA, Horgan K, Zheng H, Ryan DP. A phase II study of gemcitabine (G), bevacizumab (B), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas. Proc Am Soc Clin Oncology. 2008.
View in: PubMed

Blaszkowsky LS, Zhu AX, Abrams T, Clark JW, Earle C, Kwak E, Meyerhardt J, Horgan K, Zheng K, Ryan DP. A phase II study of gemcitabine (GEM), bevacizumab (BEV), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas. Gastrointestinal Cancer Symposium. 2008.
View in: PubMed

Jackson NA, Niedwiecki D, Hollis D, Saltz L, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Meyerhardt JA. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. . To be submitted. 2008.
View in: PubMed

Meyerhardt JA, Kulke MH. Gastrointestinal Cancer. Atlas of Diagnostic Oncology (Ed: Skarin A). 2008; In editorial stage..
View in: PubMed

Jackson NA, Fuchs CS, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Meyerhardt JA. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. Proc Am Soc Clin Oncol. 2008.
View in: PubMed

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92.
View in: PubMed

Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008 Jan; 134(1):21-8.
View in: PubMed

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15; 298(7):754-64.
View in: PubMed

Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9.
View in: PubMed

Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007 Sep; 28(9):1985-90.
View in: PubMed

Clark JW, Meyerhardt JA, Sahani DV, Namasivayam S, Abrams TA, Stuart K, Bhargava P, Blaszkowsky LS, Jain SR, Zhu AX. Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. Proc Am Soc Clin Oncol. 2007.
View in: PubMed

Kulke MH, Frauenhoffer CS, Hooshmand SM, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Hornick J, Fuchs CS, Redston MS. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). Proc Am Soc Clin Oncol. 2007.
View in: PubMed

Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007 Jul; 9(7):569-77.
View in: PubMed

Blaszkowsky LS, Ryan DP, Earle C, Kwak E, Fuchs S, Meyerhardt JA, Stuart K, Zhu AX, Enzinger P, Kulke MH. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 2007.
View in: PubMed

Meyerhardt JA, Saunder M. Colorectal Cancer: Dana-Farber Cancer Institute Handbook. 2007.
View in: PubMed

Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008 Feb; 53(2):564-70.
View in: PubMed

Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9.
View in: PubMed

Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007 May-Jun; 13(3):168-74.
View in: PubMed

Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007 May-Jun; 57(3):168-85.
View in: PubMed

Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
View in: PubMed

Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007 Nov; 56(11):1564-71.
View in: PubMed

Enzinger PC, Benedetti JK, Meyerhardt JA, McCoy S, Hundahl SA, Macdonald JS, Fuchs CS. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007 Mar; 245(3):426-34.
View in: PubMed

Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
View in: PubMed

Chan AT, Giovannucci EL, Meyerhardt JA, Fuchs CS . A Prospective Study of Aspirin Dose and Duration of Use and Risk of Colorectal Cancer Among Men. Digestive Disease Week Convention. 2007.
View in: PubMed

Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006 Dec 20; 24(36):5680-6.
View in: PubMed

Meyerhardt JA. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic Colorectal Cancer. Am J of Hematology / Oncology. 2006; 5(9):568-571.
View in: PubMed

Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13.
View in: PubMed

Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61.
View in: PubMed

Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006 Aug 01; 24(22):3527-34.
View in: PubMed

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41.
View in: PubMed

Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4044.
View in: PubMed

Zhu AX, Blaszkowsky L, Enzinger PC, Bhargava P, Ryan DP, Meyerhardt J, Horgan K, Hale K, Sheehan S, Stuart K. Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14096.
View in: PubMed

Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93.
View in: PubMed

Meyerhardt JA, Stuart K, Zhu A, Fuchs C, Bhargava P, Earle C, Blaszkowsky L, Lawrence C, Battu S, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3545.
View in: PubMed

Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):59-65.
View in: PubMed

Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7.
View in: PubMed

Chan AT, Meyerhardt JA, Giovannucci EL, Chan JA, Schernhammer ES, Fuchs CS. . Aspirin Use and Survival after Diagnosis of Colorectal Cancer. Digestive Disease Week Convention. 2006.
View in: PubMed

Kulke MH , Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS . A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol. 2006.
View in: PubMed

Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006 Jan; 19(1):59-68.
View in: PubMed

Enzinger PC, Fidias P, Meyerhardt JA, Stuart K, Fuchs C, Huberman M, Goldstein M, Freter R, Attawia M, Lawrence C, Zhu A . Phase II study of bevacizumab and docetaxel (AvaTax) in metastatic esophageal and gastric cancer. Gastrointestinal Cancer Sympsosium. 2006.
View in: PubMed

Meyerhardt JA. The overtreatment of patients with stage II disease [colon cancer]. ASCO News and Forum. 2006; 1(4):18-19.
View in: PubMed

Enzinger PC, Fidias P, Meyerhardt J, Stuart K, Fuchs C, Huberman M, Goldstein R, Attawia M, Lawrence C, Zhu AX . Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Proc Am Soc Clin Oncol. 2006.
View in: PubMed

Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
View in: PubMed

Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
View in: PubMed

Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005 Aug 24; 294(8):914-23.
View in: PubMed

Fuchs C, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, Saltz LB, Schilsky RL, Mayer RJ. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3530.
View in: PubMed

Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1402-10.
View in: PubMed

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schilsky RL, Fuchs CS. The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3534.
View in: PubMed

Clark JW, Zhu AX, Ryan DP, Meyerhardt J, Enzinger P, Earle C, Fuchs C, Anbe H, Houghton M, Kulke M. Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). J Clin Oncol. 2005 Jun; 23(16_suppl):4066.
View in: PubMed

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005 Feb 03; 352(5):476-87.
View in: PubMed

Fuchs CS, Meyerhardt JA, Brady D, Niedzwiecki D, Hollis D, Chan AT, Saltz LB, Mayer RJ, Goldberg RM, Schilsky RL. . Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. Proc Am Soc Clin Oncol. 2005.
View in: PubMed

Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke M, Ryan D, Langford L, Michelini A, Meyerhardt JA. . Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced solid tumors. Gastrointestinal Cancer Symposium. 2005.
View in: PubMed

Meyerhardt JA, Fuchs CS. Epidermal growth factor receptor inhibitors and colorectal cancer. Oncology (Williston Park). 2004 Dec; 18(14 Suppl 14):35-8.
View in: PubMed

Meyerhardt JA, Xhu A, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Michelini A, Vincitore M, Thomas A, Fuchs CS. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3580.
View in: PubMed

Fuchs C, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3521.
View in: PubMed

Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4040.
View in: PubMed

Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46.
View in: PubMed

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB, Fuchs CS. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004 Feb 15; 22(4):648-57.
View in: PubMed

Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. . Phase II study of docetaxel, cisplatin, and irinotecan (TPC) in advanced esophageal and gastric cancer. Proc Am Soc Clin Oncol. 2004.
View in: PubMed

Enzinger PC, Mamon H, Choi N, Bueno R, Kulke M, Fidias P, Donahue D, Mentzer S, Morgan J, Sugarbaker D, Liu G, Meyerhardt J, Wain J, Jaklitsch M, Lee J, Wright C, Michelini A, Ostler P, Langford L, Lynch T. Phase II Cisplatin, Irinotecan, Celecoxib and Concurrent Radiation Therapy Followed by Surgery for Locally Advanced Esophageal Cancer. Gastrointestinal Cancer Symposium. 2004.
View in: PubMed

Meyerhardt JA. Can an Optimal First-Line Therapy be Identified for Metastatic Colorectal Cancer?. Am J Oncol Rev. 2004; 3:460-3.
View in: PubMed

Meyerhardt JA and Fuchs CS. Epidermal Growth Factor Receptor Inhibitors and Colorectal Cancer. Oncology. 2004; 18(14 Suppl 14):35-8.
View in: PubMed

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 01; 22(1):166-74.
View in: PubMed

Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke M, Ryan D, Langford L, Michelini A, Meyerhardt JA. Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced solid tumors. ESMO. 2004.
View in: PubMed

Fuchs CS, Pollak M, Sargent DJ, Meyerhardt J, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM. . Insulin-Like Growth Factor-I (IGF-1), IGF Binding Protein-3 (IGFBP-3), and Outcome in Metastatic Colorectal Cancer (CRC): Results from Intergroup Trial N9741. Proc Am Soc Clin Oncol. 2004.
View in: PubMed

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
View in: PubMed

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003 Aug 01; 98(3):484-95.
View in: PubMed

Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol. 2003 Jun; 30(3):349-60.
View in: PubMed

Meyerhardt JA, Fuchs CS. Adjuvant therapy in gastric cancer: can we prevent recurrences? Oncology (Williston Park). 2003 May; 17(5):714-21, 728; discussion 728-9, 732-3.
View in: PubMed

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 01; 21(3):433-40.
View in: PubMed

Meyerhardt JA and Fuchs CS. Adjuvant Therapy in Gastric Cancer: Can We Prevent Recurrences?. Oncology (Huntingt). 2003; 17:714-21.
View in: PubMed

Meyerhardt JA and Fuchs CS . Gastric Cancer. Clinical Practice of Hematology and Oncology: Presentation, Diagnosis and Treatment (Ed: Mayer RJ, Furie B, Cassileth PA, and Atkins MB). 2003; 887-898.
View in: PubMed

Meyerhardt JA, Fuchs CS. Chemotherapy options for gastric cancer. Semin Radiat Oncol. 2002 Apr; 12(2):176-86.
View in: PubMed

Meyerhardt JA and Fuchs CS. Chemotherapy in advanced gastric cancer. Seminars in Radiation Oncology. 2002; 12:176-86.
View in: PubMed

Reyes-Múgica M, Meyerhardt JA, Rzasa J, Rimm DL, Johnson KR, Wheelock MJ, Reale MA. Truncated DCC reduces N-cadherin/catenin expression and calcium-dependent cell adhesion in neuroblastoma cells. Lab Invest. 2001 Feb; 81(2):201-10.
View in: PubMed

Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, Look AT, Fearon ER. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas. Cell Growth Differ. 1999 Jan; 10(1):35-42.
View in: PubMed

Meyerhardt JA, Look AT, Bigner SH, Fearon ER. Identification and characterization of neogenin, a DCC-related gene. Oncogene. 1997 Mar 13; 14(10):1129-36.
View in: PubMed

Meyerhardt JA. Studies of a DCC-related protein and a candidate DCC ligand: The cloning and characterization of the human homologues of neogenin and netrin-1. 1997.
View in: PubMed

Guerder S, Meyerhardt J, and Flavell R. The Role of the T Cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity. 1994; 1:155-166.
View in: PubMed

Evans R, Fong M, Fuller J, Kamdar S, Meyerhardt J, Strassmann G. Tumor cell IL-6 gene expression is regulated by IL-1 alpha/beta and TNF alpha: proposed feedback mechanisms induced by the interaction of tumor cells and macrophages. J Leukoc Biol. 1992 Oct; 52(4):463-8.
View in: PubMed

Kilpatrick DL, Zinn SA, Fitzgerald M, Higuchi H, Sabol SL, Meyerhardt J. Transcription of the rat and mouse proenkephalin genes is initiated at distinct sites in spermatogenic and somatic cells. Mol Cell Biol. 1990 Jul; 10(7):3717-26.
View in: PubMed

Top